Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain ...

The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and ...

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global ...

and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform. GQ Bio is a privately held biopharmaceutical company with a novel, high-capacity ...

Pacira (PCRX) announced it has acquired the remaining 81% equity stake of GQ Bio Therapeutics for approximately $32M, net of working capital ...

PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in ...

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

A study led by UMass Chan Medical School researchers has demonstrated that a gene therapy to correct a mutation that causes ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...